Rate of EGFR mutation in patients with pulmonary adenocarcinoma

Waqas Shuaib, Aisha Kousar, Nosheen Anwar Bejori, Asim Saeed, Emilio Valdes, Moeed Ahmad, Saleem Khawaja, Tariq Baloch

Abstract


Purpose: Contemporary literature on lung adenocarcinoma has demonstrated a genetic difference of the epidermal growth factor receptor (EGFR) pathway conferring to ethnicity, such as higher frequency of activated EGFR mutations in East Asian population. This information is missing in some developing countries, and we intend to address this gap in the literature.

Methods: We examined the rate of EGFR mutations among Pakistani patients with adenocarcinoma of the lung. Fine-needle aspiration samples were gathered from 73 patients. Polymerase chain reaction was performed on extracted DNA for mutational analysis of EGFR exons 19 and 21.

Results: EGFR mutations were discovered in 18 of 73 (24.6%) patients. We did not find any significant difference in EGFR mutation rate with regard to patient's age, sex, smoking history, clinical stage of lung cancer, subtypes of adenocarcinoma, and tumor differentiation.

Conclusion: Our investigation shows that the EGFR mutation rate in our patient population with adenocarcinoma of the lung was higher than in African-American, Arabian, and white Caucasian patients, and was lower than the East Asian population.


Keywords


Adenocarcinoma; EGFR; Mutation; Lung Cancer

Full Text:

PDF HTML

References


Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-11.

Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.

Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.

Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006; 24:2158-63.

Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008; 21 Suppl 2:S16-22.

Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-9.

Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005; 23:8081-92.

Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-57.

Leidner RS, Fu P, Clifford B, et al. Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 2009; 27:5620-6.

Al-Kuraya K, Siraj AK, Bavi P, et al. High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Hum Pathol 2006; 37:453-7.

Sahoo R, Harini VV, Babu VC, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 2011; 73:316-9.

Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919-23.

Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005; 23:2493-501.




DOI: http://dx.doi.org/10.14319/ijcto.0204.20

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

------------------------------------------------------------

International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.

------------------------------------------------------------

Number of visits since October, 2013
AmazingCounters.com